Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer
BARCELONA – Benefit was particularly pronounced in patients with a tumor BRCA mutation and those with homologous recombination deficiency (HRD)–...
News
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
News
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroups
BARCELONA – Combination nivolumab and ipilimumab showed good safety and encouraging clinical activity in patients with advanced NSCLC, despite...
News
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
News
Cancer drug prices higher in U.S. than Europe; don’t correlate with clinical benefit
BARCELONA – Cancer drug prices are significantly higher in the United states than in Europe, and they don’t correlate with clinical benefit in...
News
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
News
OS benefit with pembrolizumab endures long-term in advanced NSCLC
BARCELONA – First-line pembrolizumab provides a durable long-term OS benefit, compared with that of chemotherapy, in patients with advanced...
News
IMpower131: Improvement in OS for stage IV NSCLC+high-PD-L1 expression
BARCELONA – Patients in the IMpower131 trial with high PD-L1 expression experienced a clinically meaningful improvement in OS with atezolizumab +...
News
Tissue TMB disappoints as treatment response biomarker in NSCLC
BARCELONA – Tissue TMB was not significantly associated with treatment efficacy in patients with metastatic nonsquamous NSCLC in the phase 3...
News
LDCT plus miRNA bolsters prevention efforts
BARCELONA – Adding miRNA testing to LDCT lung cancer screening improves prevention efforts with no detrimental effects in lung cancer detection or...
News
MYSTIC trial analysis IDs mutations prognostic of mNSCLC outcomes
An exploratory analysis of MYSTIC trial specimens shows that mutations in the tumor suppressor KEAP1, STK11, and ARID1a genes in mNSCLC genes have...
News
IASLC survey: Ongoing and intensified molecular testing education needed globally
The top five barriers to the use of molecular testing included cost, quality, access, awareness, and time.
News
New IASLC declaration targets tobacco use among cancer patients
BARCELONA – The IASLC has released a new declaration encouraging physicians to screen all cancer patients for tobacco use and to provide tobacco...
News
High-dose vitamin D for bone health may do more harm than good
A randomized trial showed an inverse dose-response relationship between high-dose vitamin D supplementation and bone quality in healthy adults.